Background
Our research draws great distinction from typical Wall Street sell side analyst report. Our emphasis is not on income statement and quarterly revenue, but rather on underlying scientific mechanism, clinical trial analysis including design and readout, as well as projection on a drug’s addressable population. Our panel of experts are mostly conducting research in the fields of:
Oncology, especially in elucidating the etiology of cancer.
Neurodegeneration, with focus on the inherent causes.
Model Portfolio
Our model portfolio encapsulates our current views on the industry.